Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure

Journal of Perinatology volume 28, pages 405–411 (2008)Cite this article

Abstract

Objective:

Previous reports suggest a benefit of fluconazole prophylaxis in extremely low birth weight (ELBW) infants <1000 g. Our aim was to evaluate if limiting fluconazole prophylaxis to targeted highest risk infants effectively prevents invasive fungal infections, has no undesired side effects and limits unnecessary drug exposure.

Study Design:

This nonrandomized retrospective pre-post intervention study compared two groups of infants: (1) Infants <26 weeks gestation and/or <750 g birth weight, requiring central vascular access and admitted to the Monroe Carell Jr Children's Hospital at Vanderbilt neonatal intensive care unit (NICU) prior to 5 days of age, who received fluconazole prophylaxis and (2) a matched control group from the year prior to prophylaxis. This target population was selected for fluconazole prophylaxis based on prior infection control data from our institution and a number needed to treat of <15 to prevent one episode of fungemia. Following implementation and integration through the institution's computerized physician order entry (CPOE) system, provider adherence to the protocol was assessed during the prophylaxis period.

Result:

A total of 86 patients were included in the study, 44 in the no-prophylaxis group and 42 in the prophylaxis group. In the targeted prophylaxis group, no invasive fungal infections were observed as compared to nine infants with invasive infections in the no-prophylaxis group (P=0.004). No significant adverse effects were recorded. Targeting the highest risk infants reduced the number of infants <1000 g requiring prophylaxis from 80 to 42 (48% reduction) with no preventable infection missed. Provider compliance was 91% following implementation of this protocol through the CPOE system using a standardized order set.

Conclusion:

Targeting the highest risk infants for fluconazole prophylaxis through CPOE can effectively prevent invasive fungal infections and limit drug exposure with no unwanted side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285–291.

    Article  Google Scholar 

  2. Feja KN, Wu F, Roberts K, Loughrey M, Nesin M, Larson E et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr 2005; 147: 156–161.

    Article  Google Scholar 

  3. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000; 19: 319–324.

    Article  CAS  Google Scholar 

  4. Benjamin Jr DK, Ross K, McKinney Jr RE, Benjamin DK, Auten R, Fisher RG . When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 2000; 106: 712–718.

    Article  Google Scholar 

  5. Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA . Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78: 225–232.

    CAS  PubMed  Google Scholar 

  6. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20: 1119–1124.

    Article  CAS  Google Scholar 

  7. Kaufman D, Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660–1666.

    Article  CAS  Google Scholar 

  8. Smith PB, Morgan J, Benjamin JD, Fridkin SK, Sanza LT, Harrison LH et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J 2007; 26: 197–200.

    Article  Google Scholar 

  9. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB . Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of &lt;1000 grams birth weight. J Pediatr 2005; 147: 172–179.

    Article  CAS  Google Scholar 

  10. Healy CM, Baker CJ, Zaccaria E, Campbell JR . Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005; 147: 166–171.

    Article  CAS  Google Scholar 

  11. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF . Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005; 147: 162–165.

    Article  CAS  Google Scholar 

  12. Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006; 117: e22–e32.

    Article  Google Scholar 

  13. McCrossan BA, McHenry E, O'Neil F, Ong G, Sweet DG . Selective fluconazole prophylaxis in high risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007; 92: F454–F458.

    Article  Google Scholar 

  14. Uko S, Soghier LM, Vega M, Marsh J, Reinersman GT, Herring L et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006; 117: 1243–1252.

    Article  Google Scholar 

  15. Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356: 2483–2495.

    Article  CAS  Google Scholar 

  16. Aghai ZH, Mudduluru M, Nakhla TA, Amendolia B, Longo D, Kemble N et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006; 26: 550–555.

    Article  CAS  Google Scholar 

  17. McGuire W, Clerihew L, Austin N . Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004; (1): CD003850.

  18. Martinez Sesmero JM, Farfan Sedano FJ, Molina Garcia T, Brussi MM, Sanchez-Rubio Ferrandez J, Diez Fernandez R et al. Fungal chemoprophylaxis with fluconazole in preterm infants. Pharm World Sci 2005; 27: 475–477.

    Article  CAS  Google Scholar 

  19. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y . Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 14: 919–924.

    CAS  PubMed  Google Scholar 

  20. Playford EG, Webster AC, Sorell TC, Craig JC . Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; (3): CD004291.

  21. Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK . Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics 2006; 118: e1019–e1026.

    Article  Google Scholar 

  22. Long SS, Stevenson DK . Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr 2005; 147: 135–141.

    Article  Google Scholar 

  23. Fanaroff AA . Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics 2006; 117: 214–215.

    Article  Google Scholar 

  24. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T . Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics 2006; 117: 1680–1687.

    Article  Google Scholar 

  25. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253–258.

    Article  CAS  Google Scholar 

  26. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555–4560.

    Article  CAS  Google Scholar 

  27. Novelli V, Holzel H . Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955–1960.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Steven Steele, RN, for his assistance in data retrieval for this study. We thank Russell Waitman, PhD and the Vanderbilt WizOrder Team for their continued CPOE support as well as William Walsh, MD and Judy Aschner, MD, for review of the manuscript and helpful discussions. This study has been acknowledged by the Vanderbilt Infection Prevention (VIP) award to one of the authors (JHW).

Author information

Authors and Affiliations

  1. Division of Neonatology, Department of Pediatrics, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, USA

    J-H Weitkamp

  2. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

    A Ozdas

  3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

    B LaFleur

  4. Department of Pharmacy, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, USA

    A L Potts

Authors
  1. J-H Weitkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Ozdas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B LaFleur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A L Potts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-H Weitkamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weitkamp, JH., Ozdas, A., LaFleur, B. et al. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 28, 405–411 (2008). https://doi.org/10.1038/sj.jp.7211914

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211914

Keywords

This article is cited by

Search

Advanced search

Quick links